You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Express Scripts
McKinsey
Moodys
Johnson and Johnson

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur-uracil


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tegafur-uracil?

Tegafur-uracil is an investigational drug.

There have been 81 clinical trials for Tegafur-uracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Fudan University, and Taiho Oncology, Inc.

There are four hundred and twenty-seven US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Tegafur-uracil
TitleSponsorPhase
CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical CancerPeking Union Medical College HospitalPhase 1/Phase 2
SBRT With S1 Combined With Endostar in the Treatment of Lung CancerBeijing Cancer HospitalN/A
SBRT With S1 Combined With Endostar in the Treatment of Lung CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesN/A

See all Tegafur-uracil clinical trials

Clinical Trial Summary for Tegafur-uracil

Top disease conditions for Tegafur-uracil
Top clinical trial sponsors for Tegafur-uracil

See all Tegafur-uracil clinical trials

US Patents for Tegafur-uracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur-uracil   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Tegafur-uracil   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tegafur-uracil   Start Trial Molecular constructs with targeting and effector moieties   Start Trial
Tegafur-uracil   Start Trial Glutaminase inhibitors and method of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tegafur-uracil   Start Trial Methods and compositions for inhibition of Ras ARAXES PHARMA LLC (San Diego, CA)   Start Trial
Tegafur-uracil   Start Trial Inhibitors of ACK1/TNK2 tyrosine kinase H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)   Start Trial
Tegafur-uracil   Start Trial Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur-uracil

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur-uracil World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Tegafur-uracil Australia 2015231053 2034-03-21   Start Trial
Tegafur-uracil Brazil 112016021620 2034-03-21   Start Trial
Tegafur-uracil Canada 2943339 2034-03-21   Start Trial
Tegafur-uracil China 106231900 2034-03-21   Start Trial
Tegafur-uracil Eurasian Patent Organization 201691896 2034-03-21   Start Trial
Tegafur-uracil European Patent Office 3119199 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Dow
Baxter
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.